Pfenex Inc. (NYSEMKT:PFNX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Following Dr.Wagner’s resignation and effective October13, 2017, Evert B. Schimmelpennink our President, Chief Executive Officer, and Secretary will serve as our acting Principal Financial Officer in addition to continuing as our President, Chief Executive Officer, and Secretary.
Mr.Schimmelpennink, age 45, has served as our President, Chief Executive Officer, and Secretary since August3, 2017. Mr.Schimmelpennink previously served as the Chief Executive Officer of Alvotech, a biosimilar development
company from 2015 to July 2017. From September 2015 to November 2015, Mr.Schimmelpennink served as Vice President – Global Sterile Injectables of Pfizer Inc., a pharmaceutical company. Prior to that, Mr.Schimmelpennink served as Vice President—Global Generics from 2012 to 2015 and Director of Specialty Injectable Pharma Marketing EMEA& Director of Distributor Operations EMEA from 2011 to 2012 of Hospira, Inc., a pharmaceutical company. From 2002 to 2011, Mr.Schimmelpennink held various roles at Synthon BV, a generics medicine company, including Vice President Marketing and Sales from 2008 to 2011. From 1997 to 2002 he held various roles with Numico NV, a Dutch maker of baby foods and nutritional bars and shakes, including International Product Manager from 2000 to 2002 and Researcher Product Development from 1999 to 2000. Prior to Numico, Mr.Schimmelpennink served as a vaccine technologist at the Dutch National Institute for Public Health and the Environment from 1998 to 1999. Mr.Schimmelpennink received a Masters in bioprocess engineering from the Wageningen University in the Netherlands.
No new compensatory arrangements were entered into with Mr.Schimmelpennink in connection with his appointment as acting Principal Financial Officer. There are no family relationships between Mr.Schimmelpennink and any of our directors or executive officers. There are no transactions between Mr.Schimmelpennink and us which are reportable under Item404(a) of Regulation S-K.
Our Board of Directors has also begun the search for our next Chief Financial Officer, and will work with an executive search firm to assist in identifying and evaluating candidates.
|Item 5.02||Financial Statements and Exhibits.|
Pfenex Inc. ExhibitEX-10.1 2 d446822dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 MUTUAL SEPARATION AGREEMENT AND MUTUAL RELEASE This Mutual Separation Agreement and Mutual Release (Agreement) is made by and between Paul Wagner,…To view the full exhibit click
About Pfenex Inc. (NYSEMKT:PFNX)
Pfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Its next advanced product candidates are PF530 and PF708. PF530 is a biosimilar candidate to Betaseron (interferon beta-1b). PF708 is being developed as a therapeutically equivalent peptide to Forteo (teriparatide), which is for the treatment of osteoporosis. In addition to its three advanced product candidates, its pipeline includes over four other biosimilar candidates, as well as vaccines and next generation biologic candidates. Its product candidates are enabled by its protein production platform, Pfenex Expression Technology. It is also developing Px563L, an anthrax vaccine candidate, and Px533 as a prophylactic vaccine candidate against malaria infection.